Filter search criteria using below inputs
Click on magnifying glass icon to search
Company | Country | Symbol |
---|
Time | Volume | OVID |
---|---|---|
09:32 ET | 1976 | 3.12 |
09:38 ET | 2428 | 3.06 |
09:39 ET | 200 | 3.07 |
09:41 ET | 200 | 3.06 |
09:45 ET | 115 | 3.07 |
09:52 ET | 2200 | 3.1 |
09:56 ET | 650 | 3.128 |
09:59 ET | 590 | 3.11 |
10:01 ET | 600 | 3.11 |
10:10 ET | 200 | 3.1 |
10:12 ET | 200 | 3.1 |
10:15 ET | 1180 | 3.085 |
10:17 ET | 100 | 3.08 |
10:21 ET | 100 | 3.08 |
10:24 ET | 100 | 3.075 |
10:32 ET | 200 | 3.045 |
10:35 ET | 100 | 3.045 |
10:48 ET | 456 | 3.04 |
11:09 ET | 100 | 3.05 |
11:22 ET | 6002 | 3.03 |
11:40 ET | 100 | 3.01 |
11:45 ET | 100 | 3.01 |
11:56 ET | 400 | 3.01 |
12:05 ET | 100 | 3.01 |
12:09 ET | 100 | 3.01 |
12:14 ET | 100 | 3.01 |
12:16 ET | 100 | 3.04 |
12:20 ET | 100 | 3.01 |
12:21 ET | 100 | 3.01 |
12:27 ET | 700 | 3.01 |
12:30 ET | 100 | 3 |
12:38 ET | 100 | 3 |
12:41 ET | 1017 | 3.02 |
12:43 ET | 100 | 3.01 |
12:45 ET | 100 | 3.03 |
12:52 ET | 300 | 3.03 |
12:59 ET | 100 | 3.02 |
01:01 ET | 2250 | 3.055 |
01:03 ET | 200 | 3.065 |
01:10 ET | 100 | 3.07 |
Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
---|---|---|---|
Ovid Therapeutics Inc | 210.0M | -4.3x | --- |
Quantum-Si Inc | 209.9M | -2.3x | --- |
Candel Therapeutics Inc | 212.8M | -6.0x | --- |
Opthea Ltd | 214.3M | -1.0x | --- |
Prelude Therapeutics Inc | 206.0M | -2.1x | --- |
Boundless Bio Inc | 214.1M | 0.0x | --- |
Ovid Therapeutics Inc. is a biopharmaceutical company. The Company is focused on improving the lives of people affected by certain epilepsies and brain conditions with seizure symptoms. It is engaged in advancing a pipeline of novel, targeted small molecule candidates that modulate the intrinsic and extrinsic factors involved in neuronal hyperexcitability causative of seizures and other neurological symptoms. It develops OV888 (GV101), a potent and highly selective ROCK2 inhibitor, for the potential treatment of lesions associated with cerebral cavernous malformations and other brain disorders; OV329, a GABA-aminotransferase inhibitor, a potential therapy for treatment-resistant seizures; and OV350, a direct activator of the KCC2 transporter, for the potential treatment of epilepsies and other psychiatric conditions. It also has interest in the development and commercialization of soticlestat, which is a cholesterol 24-hydroxylase inhibitor for Dravet and Lennox-Gastaut syndromes.
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $210.0M |
---|---|
Revenue (TTM) | $473.5K |
Shares Outstanding | 70.9M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 0.55 |
EPS | $-0.72 |
Book Value | $1.24 |
P/E Ratio | -4.3x |
Price/Sales (TTM) | 443.5 |
Price/Cash Flow (TTM) | --- |
Operating Margin | -13,052.22% |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.